Pharmaceutical

IMIDomics to license TNAX’s drug candidate for IMIDs

IMIDomics has entered an agreement to license TNAX Biopharma’s IMB1001 to treat immune-mediated inflammatory diseases (IMIDs).

Sep 7, 2023 - 20:00
IMIDomics to license TNAX’s drug candidate for IMIDs
IMIDomics has entered an agreement to license TNAX Biopharma’s IMB1001 to treat immune-mediated inflammatory diseases (IMIDs).
Read the original article

Tags:

Previous Article

Veracyte and Gustave Roussy announce partnership for cancer therapies

Next Article

Novo Nordisk and Broad Institute to explore drug targets for diabetes, CMDs 

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: European regulators tout their accomplishments against pharma’s anticompetitive practices

STAT+: European regulators tout their accomplishments a...

Jan 30, 2024

Oncology biosimilar case studies: rituximab biosimilars

Oncology biosimilar case studies: rituximab biosimilars

May 20, 2023

NHS rolls out “more convenient” Ocrevus injection for multiple sclerosis

NHS rolls out “more convenient” Ocrevus injection for m...

Jul 14, 2024